Y-mAbs Therapeutics (NASDAQ:YMAB) Price Target Cut to $14.00 by Analysts at Truist Financial

Y-mAbs Therapeutics (NASDAQ:YMAB) had its price target reduced by Truist Financial from $18.00 to $14.00 in a report issued on Wednesday morning,Benzinga reports. Truist Financial currently has a buy rating on the stock.

Other equities research analysts have also recently issued reports about the stock. HC Wainwright lowered their price objective on shares of Y-mAbs Therapeutics from $22.00 to $12.00 and set a “buy” rating on the stock in a research note on Friday, March 21st. Morgan Stanley lowered their price target on shares of Y-mAbs Therapeutics from $11.00 to $7.00 and set an “underweight” rating on the stock in a research report on Wednesday, March 5th. Oppenheimer dropped their price objective on shares of Y-mAbs Therapeutics from $21.00 to $20.00 and set an “outperform” rating for the company in a research note on Wednesday. Wedbush reaffirmed an “outperform” rating and issued a $23.00 target price on shares of Y-mAbs Therapeutics in a research note on Monday, March 3rd. Finally, Bank of America cut Y-mAbs Therapeutics from a “neutral” rating to an “underperform” rating and set a $3.00 target price on the stock. in a report on Tuesday, April 22nd. Two equities research analysts have rated the stock with a sell rating, seven have assigned a buy rating and two have given a strong buy rating to the stock. According to data from MarketBeat.com, the stock presently has a consensus rating of “Moderate Buy” and an average price target of $16.70.

Y-mAbs Therapeutics Price Performance

YMAB opened at $3.64 on Wednesday. Y-mAbs Therapeutics has a 1-year low of $3.63 and a 1-year high of $16.11. The stock has a market cap of $164.81 million, a P/E ratio of -6.74 and a beta of 0.53. The stock’s 50 day simple moving average is $4.50 and its 200 day simple moving average is $7.26.

Y-mAbs Therapeutics (NASDAQ:YMAB) last posted its earnings results on Tuesday, May 13th. The company reported ($0.12) EPS for the quarter, topping analysts’ consensus estimates of ($0.22) by $0.10. Y-mAbs Therapeutics had a negative return on equity of 24.61% and a negative net margin of 28.22%. The company had revenue of $20.90 million for the quarter, compared to the consensus estimate of $19.97 million. Research analysts expect that Y-mAbs Therapeutics will post -0.65 EPS for the current fiscal year.

Insider Activity

In related news, insider Thomas Gad sold 10,810 shares of the business’s stock in a transaction that occurred on Friday, March 7th. The shares were sold at an average price of $5.23, for a total value of $56,536.30. Following the completion of the sale, the insider now directly owns 202,721 shares in the company, valued at approximately $1,060,230.83. The trade was a 5.06% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through the SEC website. Company insiders own 22.50% of the company’s stock.

Hedge Funds Weigh In On Y-mAbs Therapeutics

A number of large investors have recently bought and sold shares of the stock. Acorn Capital Advisors LLC acquired a new stake in shares of Y-mAbs Therapeutics during the 4th quarter worth $22,408,000. Caligan Partners LP grew its position in Y-mAbs Therapeutics by 47.9% during the fourth quarter. Caligan Partners LP now owns 1,767,982 shares of the company’s stock valued at $13,843,000 after acquiring an additional 572,729 shares during the period. Infinitum Asset Management LLC acquired a new stake in Y-mAbs Therapeutics during the fourth quarter worth about $1,218,000. Paradigm Biocapital Advisors LP raised its holdings in shares of Y-mAbs Therapeutics by 3.7% in the 4th quarter. Paradigm Biocapital Advisors LP now owns 4,236,346 shares of the company’s stock worth $33,171,000 after purchasing an additional 150,000 shares during the period. Finally, Boothbay Fund Management LLC lifted its stake in shares of Y-mAbs Therapeutics by 24.4% in the 4th quarter. Boothbay Fund Management LLC now owns 693,693 shares of the company’s stock valued at $5,432,000 after purchasing an additional 136,264 shares in the last quarter. Hedge funds and other institutional investors own 70.85% of the company’s stock.

About Y-mAbs Therapeutics

Y-mAbs Therapeutics, Inc, a commercial-stage biopharmaceutical company, focuses on the development and commercialization of antibody based therapeutic products for the treatment of cancer in the United States and internationally. It offers DANYELZA, a monoclonal antibody in combination with granulocyte-macrophage colony-stimulating factor for the treatment of pediatric patients with relapsed or refractory high-risk neuroblastoma in the bone or bone marrow.